We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Calliditas Therapeutics AB is a biopharmaceutical company in Sweden. The company is engaged in the provision of pharmaceutical products for patients with niche indications. It is focused on the development and commercialization of the product candidate Nefecon intended for the treatment of patients ... Calliditas Therapeutics AB is a biopharmaceutical company in Sweden. The company is engaged in the provision of pharmaceutical products for patients with niche indications. It is focused on the development and commercialization of the product candidate Nefecon intended for the treatment of patients with the inflammatory renal disease IgA nephropathy, a disease that causes chronic inflammation of the kidneys. Show more
Calliditas Therapeutics' 2023 Annual Report Published PR Newswire STOCKHOLM, April 24, 2024 STOCKHOLM, April 24, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT), (NASDAQ STOCKHOLM:...
Calliditas Therapeutics' 2023 Annual Report Published PR Newswire STOCKHOLM, April 24, 2024 STOCKHOLM, April 24, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT), (NASDAQ STOCKHOLM:...
Calliditas Announces Positive NefIgArd Open Label Extension Results PR Newswire STOCKHOLM, April 24, 2024 STOCKHOLM, April 24, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT...
Calliditas Announces Positive NefIgArd Open Label Extension Results PR Newswire STOCKHOLM, April 24, 2024 STOCKHOLM, April 24, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT...
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024 PR Newswire STOCKHOLM...
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024 PR Newswire STOCKHOLM...
Calliditas Therapeutics to Attend Conferences in April PR Newswire STOCKHOLM, April 9, 2024 STOCKHOLM, April 9, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm:...
Calliditas Therapeutics to Attend Conferences in April PR Newswire STOCKHOLM, April 9, 2024 STOCKHOLM, April 9, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm:...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
